ロード中...
Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
BACKGROUND: Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on eosinophils. Both therapies reduce oral cort...
保存先:
| 出版年: | Allergy Asthma Clin Immunol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7789431/ https://ncbi.nlm.nih.gov/pubmed/33407869 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-020-00507-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|